Celerion
Lincoln, Nebraska, 68502, United States
NCT Number: NCT05541315
The purpose of this study is to assess the safety and tolerability of a single oral dose of JNJ-88260237 in healthy participants
Looking for future studies?
Notify Me25 year–55 year
All sexes
Interventional
Phase 1
Lincoln, Nebraska, 68502, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
JNJ-88260237 will be administered orally.
Matching placebo will be administered orally.
Time frame: Up to Day 14
Number of participants with AEs will be reported.
Time frame: Up to Day 24
Number of participants with AEs will be reported.
Time frame: Up to Day 7
Number of participants with abnormalities in vital signs (including body temperature, pulse rate, respiratory rate, and blood pressure) will be reported.
Time frame: Up to Day 21
Number of participants with abnormalities in vital signs (including body temperature, pulse rate, respiratory rate, and blood pressure) will be reported.
Time frame: Up to Day 7
Number of participants with abnormalities in ECGs (digital 12-lead ECGs/Holter ECGs) will be reported.
Time frame: Up to Day 21
Number of participants with abnormalities in ECGs (digital 12-lead ECGs/Holter ECGs) will be reported.
Time frame: Up to Day 7
Number of participants with Abnormalities in clinical safety laboratory parameters (including hematology, clinical chemistry, and urinalysis) will be reported.
Time frame: Up to Day 21
Number of participants with Abnormalities in clinical safety laboratory parameters (including hematology, clinical chemistry, and urinalysis) will be reported.
Time frame: Up to Day 7
Number of participants with abnormalities in physical examinations will be reported.
Time frame: Up to Day 21
Number of participants with abnormalities in physical examinations will be reported.
Time frame: Cohort 1 to 4 and Cohort 6: Up to Day 7; Cohort 5: Up to day 21
Cmax is defined as the maximum whole blood concentration of JNJ-88260237.
Time frame: Cohort 1 to 4 and Cohort 6: Up to Day 7; Cohort 5: Up to day 21
Tmax is defined as the time to reach the maximum whole blood concentration of JNJ-88260237.
Time frame: Cohort 1 to 4 and Cohort 6: Up to Day 7; Cohort 5: Up to day 21
AUC (0-Last) is defined as the area under the whole blood concentration versus time curve from time zero to time of the last measurable concentration of JNJ-88260237.
Time frame: Cohort 1 to 4 and Cohort 6: Up to Day 7; Cohort 5: Up to day 21
AUC (0-infinity) is defined as the area under the whole blood concentration versus time curve from time zero to infinite time of JNJ-88260237.
Time frame: Cohort 1 to 4 and Cohort 6: Up to Day 7; Cohort 5: Up to day 21
T1/2 is defined as the terminal half-life of JNJ-88260237.
Time frame: Cohort 1 to 4 and Cohort 6: Up to Day 7; Cohort 5: Up to day 21
CL/F is defined as apparent oral whole blood clearance of JNJ-88260237.
Time frame: Cohort 1 to 4 and Cohort 6: Up to Day 7; Cohort 5: Up to day 21
Vz/F is defined as the apparent volume of distribution of JNJ-88260237.
Janssen Research & Development, LLC
Industry
A Double-blind, Randomized, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-88260237 in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details